---
description: 3.2 The actors is Not covered during course and Not for exam either
---

# 3.3 The key documents

## 3.3.1 Protocol

Every well-designed study requires a protocol. **The protocol is a written agreement between the Sponsor, the Investigator\(s\), the Participants, and the Scientific Community**. It provides a comprehensive description of the study with notably the following items

* Objective\(s\)
* Treatment\(s\)
* Endpoint\(s\)
* Procedures
* Data analysis to assess the objectives.

![an example of table of content](../.gitbook/assets/image%20%2813%29.png)

### Objectives: key foundation of a good experiment

Generally, the objectives will reflect the type of comparison expected to be evaluated whether the main objective of the trial is to show Superiority, Non-Inferiority, â€¦â€”â€”é€šå¸¸ï¼Œç›®æ ‡å°†åæ˜ é¢„æœŸè¿›è¡Œè¯„ä¼°çš„æ¯”è¾ƒç±»å‹ï¼Œè€Œè¯•éªŒçš„ä¸»è¦ç›®æ ‡æ˜¯å¦æ˜¯æ˜¾ç¤ºä¼˜è¶Šæ€§ï¼ŒéåŠ£ç­‰æ€§â€¦â€¦

* Cover the different aspects of the problem and its contributing factors in a coherent way and in a logical sequence;
* Are clearly phrased in operational terms, specifying exactly what you are going to do, where, and for what purpose;
* Are realistic considering local conditions;
* Use action verbs that are specific enough to be evaluated \(Examples of action verbs are: to determine, to compare, to verify, to calculate, to describe, and to establish\). Avoid the use of vague non-action verbs \(Examples of non-action verbs: to appreciate, to understand, or to study\)
* Keep in mind that when the project is evaluated, the results will be compared to the objectives. If the objectives have not been spelled out\(è®²æ¸…æ¥š\) clearly, the project cannot be evaluated.

### Endpoints \(variable\) ï¼šthe measurable characteristics or outcomes

An endpoint is a direct or indirect measurement of a clinical or pharmacological effect and measured in the individual patient. The timepoint\(s\) or time frame at which the endpoint is assessed should be specified.

> å¯ä»¥åˆ†ä¸ºobjectiveï¼ˆsurvival, occurrence of a disease exacerbationæ¶åŒ– , a disease improvement, clinical event like stroke for instanceä¾‹å¦‚ä¸­é£ï¼‰å’Œsubjective\(pain, dyspnea scaleå‘¼å¸å›°éš¾é‡è¡¨, quality of life\)

A **surrogate endpoint \(as opposed to direct\)** is an indirect endpoint like a laboratory measure or a physical sign that is intended to be used as a **substitute** for a clinically meaningful endpoint.

![](../.gitbook/assets/image%20%281%29.png)

Use of Surrogate Endpoint assume that the treatment effect is mediated by the pathway represented by the Surrogate Endpoint. However, multiple pathways may exist.

<table>
  <thead>
    <tr>
      <th style="text-align:left">An Endpoint Hierarchy For Outcome Measures (Fleming, 2005)</th>
      <th style="text-align:left">Level of clinical validation (BEST)</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="text-align:left">Level 1: a <b>true clinical-efficacy measure</b>, outcomes that directly
        reflect tangible benefit to patients</td>
      <td style="text-align:left"></td>
    </tr>
    <tr>
      <td style="text-align:left">Level 2: a <b>validated surrogate endpoint</b> (for a specific disease setting
        and class of interventions)</td>
      <td style="text-align:left"><b>validated surrogate endpoint: </b>An endpoint supported by a clear
        mechanistic rationale and clinical data providing strong evidence that
        an effect on the surrogate endpoint predicts a specific clinical benefit.</td>
    </tr>
    <tr>
      <td style="text-align:left">Level 3: a non-validated surrogate endpoint, yet one established to be
        &#x201C;reasonably likely to predict clinical benefit&#x201D; (for a specific
        disease setting and class of interventions)</td>
      <td style="text-align:left">
        <p><b>reasonably likely surrogate endpoint</b>: An endpoint supported by
          strong mechanistic and/or epidemiologic rationale such that an effect on
          the surrogate endpoint is expected to be correlated with an endpoint intended
          to assess clinical benefit in clinical trials, but without sufficient clinical
          data to show that it is a validated surrogate endpoint.</p>
        <p></p>
        <p>Level 3 measure might be considered as <b>primary endpoint in clinical trials</b> using
          the subpart E or subpart H &#x201C;Accelerated Approval&#x201D; regulatory
          approach</p>
      </td>
    </tr>
    <tr>
      <td style="text-align:left">Level 4: a correlate that is a measure of biological activity but that
        has not been established to be at a higher level</td>
      <td style="text-align:left"><b>candidate surrogate endpoint</b>: An endpoint still under evaluation
        for its ability to predict clinical benefit.</td>
    </tr>
  </tbody>
</table>### Study Cohort or Study Population

he Study Cohort or Study Population defines the subjects/patients conditions for being eligible to participate in the trial. The criteria \(inclusion/exclusion\) must be defined and should closely reflect the targeted population.

### Study design overview

The study design overview provides a snapshot with the main characteristics of the study: treatment arms\(æ²»ç–—ç»„\), number of patients, some specific interventions,â€¦

The overview do also provide a description of the design configurationï¼ˆè®¾è®¡å¸ƒå±€ï¼‰ that can be Parallel Group Design, Cross-over Design, Factorial Design, Case-Control Design,â€¦. \(see Part II.2.2.3 and II.2.2.4 for further details\).

### Randomization and Blinding

The Randomization and Blinding section describes the method for randomization \(see Part II.2.1 & II.2.2 for further details\) as well as the level of blinding \(see \) and how it is maintained throughout the study conduct and especially in case of interim analysis.

### Data Evaluation

As part of the Data Evaluation, besides providing some details on the different data analysis intent to be performed, the section:

* Provides justification for the sample size being large enough to provide a reliable answer to the scientific questions but not too large for not exposing unnecessary patients to new treatment not fully evaluated as well as contain cost. In practice either the sample size is fairly fixed by investment considerations \(typically in early development\) or there is a formal statistical hypothesis to be ruled out. In the first case, the section consist rather in describing the expected precision of the treatment effect estimates. In the second case, the following items should be specified: the endpoint, the null/alternative hypotheses, the test statistic or decision criteria, the type I error \( $$Î±$$ \), and the type II error \( $$Î²$$ \) \(see Part II.3 for further details\). In both case, assumptions about the expected treatment effect in both control and investigational product\(s\) must be provided with appropriate references;
* Provides a description of the study cohorts or analysis population to be considered for evaluating the study objectives \(see Section3.3.4\);
* Provides the sequence of analyses that are planned to be performed: final and interim analyses together with the need for an adjustment to the type I error \(see Part II.4.4 for further details\).

### Estimand

**Estimand Conceptï¼š**

An estimand is a parameter which is to be estimated in a statistical analysis. 

{% hint style="info" %}
æ³¨æ„estimandã€estimatorä»¥åŠestimateä¹‹é—´çš„åŒºåˆ«  
                                         ![](../.gitbook/assets/image%20%282%29.png) 
{% endhint %}

An estimand reflects what is to be estimated to address the scientific question of interest events that occur after treatment initiation and either precludeï¼ˆé˜»ç¢ï¼‰ observation of the variable\(s\) or affect its interpretation

<table>
  <thead>
    <tr>
      <th style="text-align:left">Name</th>
      <th style="text-align:left">Description</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="text-align:left">Population</td>
      <td style="text-align:left">
        <p>&#x5BF9;&#x4E8E;&#x603B;&#x4F53;&#xFF0C;&#x5176;estimand should be representative
          for the population of interest:</p>
        <p>1&#x3001;Characterized through the inclusion/exclusion criteria</p>
        <p>2&#x3001;Population of Interest &#x2283; Study Population &#x2283; Analysis
          Population</p>
      </td>
    </tr>
    <tr>
      <td style="text-align:left">Endpoint</td>
      <td style="text-align:left">&#x5BF9;&#x4E8E;endpoint&#x6765;&#x8BF4;&#xFF0C;&#x5176;estimand&#x662F;Intercurrent&#xFF08;&#x4E2D;&#x9014;&#x53D1;&#x751F;&#x7684;&#xFF09;
        Events</td>
    </tr>
  </tbody>
</table>#### Strategies for addressing Intercurrent Events

* Treatment policy strategy \(TPS\): The occurrence of the intercurrent event is **irrelevant** \(ITT principle\)â€¦the intercurrent event is considered to **be part of the treatments** being compared  ğŸ“š â€”â€”å¹¶å‘äº‹ä»¶ä¸å¯é€†ï¼Œæˆä¸ºtreatmentçš„ä¸€éƒ¨åˆ†
* Composite strategy \(CS\): The occurrence of the intercurrent event is taken to be **a component of the variable/endpoint**  ğŸ“š â€”â€”å¹¶å‘äº‹ä»¶æˆä¸ºå˜é‡/ç»“æŸç‚¹çš„ä¸€éƒ¨åˆ†ã€‚ä¾‹å¦‚ï¼Œå› ä¸ºä¸­æ¯’è€Œåœæ­¢æ²»ç–—çš„ç—…äººå¯èƒ½è¢«è®¤ä¸ºæ²¡æœ‰å¾—åˆ°æˆåŠŸçš„æ²»ç–—ã€‚å¦‚æœç»“æœå˜é‡æ˜¯å·²ç»æˆåŠŸæˆ–å¤±è´¥ï¼Œåœæ­¢æ¯’æ€§æ²»ç–—å°†è¢«ç®€å•åœ°è§†ä¸ºå¦ä¸€ç§å¤±è´¥æ¨¡å¼ã€‚
* Hypothetical strategy \(HS\): A scenario is envisaged in which the intercurrent event would not occur: the value of the variable to reflect the clinical question of interest is the value which the variable would have taken in the hypothetical scenario defined  ğŸ“š è®¾æƒ³äº†ä¸€ç§ä¸ä¼šå‘ç”Ÿå¹¶å‘äº‹ä»¶çš„æƒ…å†µ:åæ˜ æ‰€ç ”ç©¶çš„ä¸´åºŠé—®é¢˜çš„å˜é‡çš„å€¼å°±æ˜¯è¯¥å˜é‡åœ¨å·²å®šä¹‰çš„å‡æƒ³æƒ…å†µä¸­æ‰€å–çš„å€¼
* Principal stratum strategy \(PSS\): Classification of subjects according to the potential occurrence of an intercurrent event on either or both treatments  ğŸ“š æ ¹æ®å¯èƒ½åœ¨å…¶ä¸­ä¸€ä¸ªæˆ–ä¸¤ä¸ªæ²»ç–—ä¸­åŒæ—¶å‘ç”Ÿçš„å¹¶å‘äº‹ä»¶å¯¹å—è¯•è€…è¿›è¡Œåˆ†ç±»ã€‚ä¾‹å¦‚äººä»¬å¯èƒ½å¸Œæœ›äº†è§£åœ¨æ¥ç§ç–«è‹—åå—æ„ŸæŸ“çš„ä¸»è¦äººç¾¤ä¸­ï¼Œæ²»ç–—å¯¹æ„ŸæŸ“ä¸¥é‡ç¨‹åº¦çš„å½±å“ã€‚
* While on treatment strategy \(WTS\): Response to treatment prior to the occurrence of the intercurrent event is of interest. Particular care is required if the occurrence of the intercurrent event differs between the treatments being compared  ğŸ“š ç ”ç©¶å…´è¶£ï¼šåœ¨å¹¶å‘äº‹ä»¶å‘ç”Ÿä¹‹å‰å¯¹æ²»ç–—çš„ååº”ã€‚ä½†å¦‚æœæ­£åœ¨æ¯”è¾ƒçš„æ²»ç–—ä¹‹é—´å‘ç”Ÿçš„å¹¶å‘äº‹ä»¶ä¸åŒï¼Œåˆ™éœ€è¦ç‰¹åˆ«æ³¨æ„

#### A thinking process

![](../.gitbook/assets/image%20%285%29.png)

#### Example â€“ Multiple Sclerosiså¤šå‘æ€§ç¡¬åŒ–

<table>
  <thead>
    <tr>
      <th style="text-align:left">Intercurrent events</th>
      <th style="text-align:left">Strategies</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td style="text-align:left">
        <p>Relapses&#x590D;&#x53D1;</p>
        <p>Treatment Discontinuation</p>
        <p>Use of other medications</p>
      </td>
      <td style="text-align:left">&#x201C;Treatment policy strategy&#x201D;, namely the value for the variable
        of interest is used regardless of whether or not these intercurrent events
        occur</td>
    </tr>
    <tr>
      <td style="text-align:left">Death not due to MS</td>
      <td style="text-align:left">&#x201C;While on treatment strategy&#x201D;, namely the response to treatment
        prior to the occurrence of the intercurrent event is of interest.</td>
    </tr>
  </tbody>
</table>æ³¨æ„ï¼šTo apply â€œTreatment Policyâ€ strategy in a design where early discontinuers are not followed extensively off treatment , it is necessary to assume noninformative missingnessã€‚è‹¥è¦åœ¨è®¾è®¡ä¸­åº”ç”¨â€œæ²»ç–—ç­–ç•¥â€ç­–ç•¥ï¼Œè€Œä¸å¹¿æ³›åœ°è·Ÿè¸ªæ—©æœŸåœè¯è€…çš„æ²»ç–—æƒ…å†µï¼Œåˆ™å¿…é¡»å‡å®šæ— ä¿¡æ¯æ€§é—æ¼

## 3.3.2 â€“ Inform Consent Formï¼ˆICFï¼‰

1ã€Subject voluntary or legally authorized representative \(LAR\) confirms willingness to participate  
2ã€ICF copy given to subject  
3ã€Information process to be well documented  
4ã€Written, signed & dated Informed Consent Form \(ICF\)

* After being informed of all aspects of study
* Prior to study participation
* Informed Consent Form \(ICF\) used to inform subject\* about research Investigational Productã€Study Proceduresã€Treatment assignmentã€Duration of trialã€Treatment Alternativesã€Risk / benefitsã€Access to medical recordsã€Confidentialityã€Payment / financial benefitsã€Contact person, etc...

## 3.3.4 â€“ Statistical Analysis Plan

More technical and detailed document describing the analyses:

* detailed statistical methods applied on the different endpoints to evaluate the different objectives
* derived variables detailed descriptions of the data transformation
* handling of missing data. ---Missing values represent a potential source of biasã€‚ç„¶è€Œå½“ç¼ºå¤±å€¼æ˜¯éšæœºçš„ï¼Œä¸ç ”ç©¶çš„æ²»ç–—ï¼ˆinvestigational treatmentï¼‰ç­‰æ— å…³ï¼Œæˆ–è€…å¤„ç†æ–¹æ¡ˆ\(protocol\)å’Œ/æˆ–ç»Ÿè®¡åˆ†æè®¡åˆ’\(SAP\)ä¸­é¢„å…ˆå®šä¹‰çš„ç¼ºå¤±å€¼çš„æ–¹æ³•æ˜¯æ˜æ™ºçš„\(sensible\)æ—¶ï¼Œå®ƒå¹¶ä¸å¦¨ç¢ä»è¯•éªŒä¸­å¾—å‡ºï¼ˆderiveï¼‰æœ‰æ•ˆçš„ç»“è®º
* Analysis population definition \(Intent To Treatæ„å›¾æ²»ç–—, According to Protocol\)

## 3.3.5 â€“ Investigator Brochure

It describes the unmet medical need, the target product profile and previous acquired data with the treatment/medicine. At the start of human research experiments, it will consist primarily or entirely of in-vitro or animal experiments. It is then regularly updated with the accrualï¼ˆç´¯ç§¯ï¼‰ of human data. Based on this document, the investigator will decide to participate in a clinical trial or not.

## 3.3.6 â€“ Common Technical Dossieræ±‡æ€»

Key Learningsï¼š

* Clinical Trials are performed to make **scientifically valid** clinical research
* A **broader perspective** is essential \(Target Product profile\(TPP\) -&gt; CDP\)
* Need for elaborating **clear questions**
* Importance to generating **valid data** \(e.g.: **control bias**\)
* **Learning** from information accrued with descriptive and inferential statistics to progress in research \(**Clinical developement plan**\) â€¦
* Interacting with different **partners**



